Peripheral Neuropathy During Concomitant Administration of Proteasome Inhibitors and Factor Xa Inhibitors: Identifying the Likelihood of Drug-Drug Interactions
Backgrounds: Proteasome inhibitors (PI) cause toxic peripheral neuropathy (PN), which is one of the dose-limiting adverse events of these treatments. Recent preclinical studies find that factor Xa inhibitor (FXaI), rivaroxaban, promotes PN in animals receiving oxaliplatin. Cancer patients can receiv...
Saved in:
Main Authors: | Long Meng (Author), Jing Huang (Author), Feng Qiu (Author), Xuefeng Shan (Author), Lin Chen (Author), Shusen Sun (Author), Yuwei Wang (Author), Junqing Yang (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2022-03-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Adverse event profiles of dipeptidyl peptidase-4 inhibitors: data mining of the public version of the FDA adverse event reporting system
by: Jing Huang, et al.
Published: (2020) -
Efficacy and Toxicity of Factor Xa Inhibitors
by: Maryna Bondarenko, et al.
Published: (2013) -
Pharmacodynamics and Pharmacokinetics of oral factor Xa inhibitors
by: Persson PB
Published: (2015) -
Measurement properties of brief neuropathy screening items in cancer patients receiving taxanes, platinums, or proteasome inhibitors
by: Robert Knoerl, et al.
Published: (2021) -
Discovery and development of Factor Xa inhibitors (2015-2022)
by: Wei Zheng, et al.
Published: (2023)